With the current explosion in the number of cell therapies moving to the clinic, we need to continue to evaluate bioprocessing technology paradigms, and how different workflows progress from early R&D to commercial manufacturing.
Fundamental questions still exist in the debate between using segmented platforms with individual unit operations or utilizing a fully automated platform.
During this webinar, we want to take a deeper look into the process development path. We will start from early process development and how this effects the considerations as we move into the clinic and ultimately, into commercial manufacturing. We will discuss how an automated manufacturing platform like the Cocoon can ease tech transfer when adopted in the early stages of development, and ensure you have a scalable solution from pre-clinical to commercial scale manufacturing. Donna Rill from Triumvira Immunologics will also share her manufacturing experience and explain why Triumvira chose to adopt a closed and automated system prior to entering clinical trials.
Attendees will learn about:
The Lonza logo is a Lonza Ltd. Trademark